PHIO — Phio Pharmaceuticals Corp

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclin… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.08
Market Cap$12.5M
Float11.5M
Shares Outstanding11.6M
P/E (Forward)0.31
Price/Sales (TTM)48.01
vs. Analyst Target+1196.3% to analyst PT
Dividend RateNone
Analyst Target Price$14.00 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $4,362 -$8.8M -$3.7M -$8.7M
2021 N/A -$13.2M -$192,000 -$13.4M
2022 N/A -$11.3M -$193,000 -$11.3M
2023 N/A -$10.8M -$6.3M -$10.6M
2024 N/A -$7.2M -$3.6M -$7.4M
2025 N/A -$8.7M -$3,000 -$9.2M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$2.2M
Sep 2025 N/A -$2.4M
Dec 2025 N/A -$2.4M
Mar 2026 N/A -$4.0M

Ownership & Float

Insider Ownership6.0%
Institutional Ownership10.8%
Short Float4.1%
% of All Funds Holding0.27%
Number of Funds Holding22

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.17Near-term / short-term trend
Weekly40-Week SMA$1.42Medium-term trend
Weekly80-Week SMA$1.74Cyclical trend (business cycle)
Weekly200-Week SMA$16.12Secular trend (multi-year)
Monthly10-Month SMA$1.45Near-term monthly trend
Monthly20-Month SMA$1.77Medium-term monthly trend
Monthly40-Month SMA$8.93Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$3.40 resistance 3.89x 5 months ago
$2.90 resistance 6.79x 16 months ago

Historical Earnings Reactions (56 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.87% 0.54% 57.14% 16.52% -10.65%
1 Day -2.01% -1.97% 32.14% 15.38% -18.97%
1 Week -5.36% -3.48% 37.50% 34.45% -86.15%
2 Weeks -3.22% -1.07% 41.07% 86.92% -87.69%
1 Month -5.05% -6.75% 36.36% 50.77% -55.17%

Next earnings: July 26, 2026 (60 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan0.9%42.9%14
Feb5.8%50.0%14
Mar-0.8%50.0%14
Apr-8.0%28.6%14
May-3.3%30.8%13
Jun3.8%50.0%14
Jul-10.6%35.7%14
Aug-4.8%28.6%14
Sep-9.2%21.4%14
Oct-13.2%21.4%14
Nov-8.3%35.7%14
Dec-13.9%14.3%14

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.09% 42.7% 662
Tuesday -0.38% 39.7% 725
Wednesday 1.00% 41.4% 722
Thursday -0.29% 38.8% 709
Friday -0.08% 41.5% 710

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 10.8%

Insider Transactions — Smart Summary

Total insider ownership: 6.0%

12-Month Insider Activity Summary

Total Filings7
Net Value+$31,265
Net Shares Change26,000
% of Float0.2%
C-Suite Filings6
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Bitterman Robert J Chairman, Pres. and CEO +$31,265 6 6 buy
Ferrara Robert L +$6,049.75 1 1 buy

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-02 Bitterman Robert J Chairman, Pres. and CEO +$5,150 Transaction at $1.03, now +4.9%
2025-12-29 Bitterman Robert J Chairman, Pres. and CEO +$5,100 Transaction at $1.02, now +5.9%
2025-06-11 Bitterman Robert J Chairman, Pres and CEO +$4,840 Transaction at $2.42, now -55.4%
2025-06-10 Bitterman Robert J Chairman, Pres and CEO +$4,125 Transaction at $2.75, now -60.7%
2025-11-24 Bitterman Robert J Chairman, Pres. and CEO +$5,700 Transaction at $1.14, now -5.3%
2025-11-19 Bitterman Robert J Chairman, Pres. and CEO +$6,350 Transaction at $1.27, now -15.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Phio Pharmaceuticals Corp (PHIO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for PHIO on Trend Edge →